<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122814">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02057172</url>
  </required_header>
  <id_info>
    <org_study_id>HM-EXC-203</org_study_id>
    <nct_id>NCT02057172</nct_id>
  </id_info>
  <brief_title>Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes</brief_title>
  <official_title>A Phase II, 12-week, Double-blind, Randomised, Parallel Group, Multi-centre, International Trial to Assess the Effect on Glycaemic Control of Five Doses of HM11260C Versus Placebo or Open-label Liraglutide in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the optimal dose or doses of HM11260C, when
      administered once a week under the skin, to improve the control of blood sugar levels in
      patients with early-stage type 2 diabetes mellitus (T2DM).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in baseline in glycosylated haemoglobin (HbA1c) at 12 weeks</measure>
    <time_frame>Up to 127 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma glucose levels (FPG)</measure>
    <time_frame>Up to 127 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7-point glucose profile</measure>
    <time_frame>Up to day 127</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other glycaemic control parameters</measure>
    <time_frame>Up to day 127</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum lipid profile</measure>
    <time_frame>Up to day 127</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>Up to day 127</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects attaining goal glycosylated haemoglobin (HbA1c) &lt;7%</measure>
    <time_frame>Up to 127 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Assess the safety and tolerability of HM11260C</measure>
    <time_frame>Up to day 127</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Assess the immunogenicity of HM11260C</measure>
    <time_frame>Up to day 127</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">252</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>HM11260C (0.3 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly administration of 0.3 mg of HMC11260C by subcutaneous injection for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HM11260C (1 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly administration of 1 mg of HM11260C by subcutaneous injection for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HM11260C (2 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly  administration of 2 mg of HM11260C by subcutaneous injection for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HM11260C (3 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly  administration of 3 mg of HM11260C by subcutaneous injection for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HM11260C (4 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly  administration of 4 mg of HM11260C by subcutaneous injection for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Weekly  administration of placebo by subcutaneous injection for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liraglutide will be administered daily, at doses of 0.6 mg to 1.8 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM11260C</intervention_name>
    <description>HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)</description>
    <arm_group_label>HM11260C (0.3 mg)</arm_group_label>
    <arm_group_label>HM11260C (1 mg)</arm_group_label>
    <arm_group_label>HM11260C (2 mg)</arm_group_label>
    <arm_group_label>HM11260C (3 mg)</arm_group_label>
    <arm_group_label>HM11260C (4 mg)</arm_group_label>
    <other_name>LAPS-Exendin-4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>Liraglutide is a GLP-1 agonist.</description>
    <arm_group_label>Liraglutide</arm_group_label>
    <other_name>Victoza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages eligible for study : 18 years to 74 years

          -  Genders eligible for study : Male and Female

          -  Diagnosed with T2DM

          -  Received diet and exercise therapy with or without metformin monotherapy

          -  HbA1c levels of between ≥ 7.0% and ≤ 10.0%

          -  Females of childbearing potential who are not pregnant and agree to use a reliable
             method of birth control

          -  Written informed consent must be obtained

        Exclusion Criteria:

          -  Pregnant or nursing (lactating) women

          -  Diagnosis of type 1 diabetes mellitus

          -  Uncontrolled diabetes defined as a FPG level of &gt; 240 mg/dL

          -  A significant change in body weight  in the 3 months before screening

          -  Any history of GI intolerance

          -  Personal or family history of medullary thyroid cancer (MTC) or a genetic condition
             that predisposes to MTC

          -  Known history of chronic pancreatitis

          -  A history of alcohol or drug abuse or drug addiction
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanmi Pharmaceutical</last_name>
    <role>Study Director</role>
    <affiliation>clinical4@hanmi.co.kr</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hanmi Pharmaceutical</last_name>
    <email>clinical4@hanmi.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hanmi pharmaceutical</name>
      <address>
        <city>CA</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanmi Pharmaceutical</last_name>
      <email>clinical4@hanmi.co.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>February 6, 2014</lastchanged_date>
  <firstreceived_date>January 30, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glycaemic control</keyword>
  <keyword>HM11260C</keyword>
  <keyword>placebo</keyword>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>type 2 diabetes mellitus</keyword>
  <keyword>efficacy</keyword>
  <keyword>T2DM</keyword>
  <keyword>glycated haemoglobin (HbA1c)</keyword>
  <keyword>glycosylated haemoglobin (HbA1c)</keyword>
  <keyword>Glucagon-Like Peptide-1 (GLP-1) agonists</keyword>
  <keyword>blood sugar levels</keyword>
  <keyword>fasting plasma glucose (FPG)</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
